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Abstract
Background: Juvenile idiopathic arthritis (JIA) is the most common pediatric chronic rheumatic disease, which
requires constant follow-up over the years, due to relapses during its progression. To maintain a good quality of life,
it is important to limit admissions as far as possible. With the development of a Diagnostic Therapeutic Assistance
Pathway (DTAP), we aim to select patients with suitable clinical conditions to be moved from routine hospital
management to day care or outpatient treatment, evaluating the number of patients to whom this would apply.
Methods: Monocentric study regarding admissions for JIA between 2014 and 2016 in a Pediatric Unit of a
university hospital in Milan. Through an analysis of the medical records, relevant information was extracted and
collected in a Microsoft™ Excel database; starting from the data collected during the first year, a DTAP was prepared
for patients with active arthritis and appropriate clinical conditions.
Results: The study includes data from 223 JIA hospitalization cases involving 127 patients. Applying DTAP criteria,
32% patients would have avoided admissions and 23% would have been admitted less frequently. The data
concerning the activities of the Unit for JIA patients showed a relevant drop in the number of hospitalizations
since 2015, from 89 in 2014 to 66 and 68 in 2015 and 2016 respectively.
Conclusion: The opportunity offered by DTAP, has suggested feasible changes in hospitalization management
and it’s use would promote the possibility of treating the children without hospitalization, or minimizing it. In
conclusion DTAP application is a priority for the continuous improvement of clinical practice and quality of life for
patients and their families.
Keywords: Juvenile idiopathic arthritis (JIA), Diagnostic therapeutic assistance pathway (DTAP), Quality of life,
Pediatrics
Background
Juvenile idiopathic arthritis (JIA) is the most common
chronic rheumatic disease (prevalence of 1: 1000) in the
pediatric field, which requires constant follow-up over
the years since its progression is characterized by
relapses [1–3]. Currently, there are no identified drugs
to cure the disease, but it is possible to keep it under
control and avoid the occurrence of injuries [4, 5].
In general, the management of a JIA patient is based
on a multi-professional approach which, in addition to
the pediatrician, also involves the nurse, the physiother-
apist and the occupational therapist [6].
At the onset, the disease is frequently treated with
non-steroidal anti-inflammatory drugs and intra-
articular corticosteroid injections [7, 8], followed by
second-level drugs such as Methotrexate or Sulfasalazine
[9, 10]. In the event that a patient with JIA, in therapy
with these drugs, manifests an unsatisfactory control of
the disease, it is recommended to initiate treatment with
biological drugs [11, 12], nowadays considered as
effective and safe in treating the disease [13, 14]. The
widespread use of biological drugs is one of the causes
of the increase in health care costs for people with JIA
in recent years; moreover, according to a European study
published in 2016, also a longer length of admissions
contributes to the increased spending [15].
Studies show that JIA involves a noticeable reduction
in quality of life in over half of affected patients [16–18];
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it therefore seems desirable to try to construct a care
flowchart to provide the necessary therapies, and keep-
ing, as far as possible, the usual level of quality of life.
For chronic pediatric diseases, JIA in particular, the im-
plementation of the Chronic Care Model is shown to be
related to an improvement in the control of the disease,
the management of symptoms and quality of life. This
model aims at a proactive management of the pathology,
and promote, among others, the use of standardized
pathways, the coordination of care and greater involve-
ment and self-management of the patient and the care-
giver [19, 20].
In this sense we can hypothesize building a pathway
which reserves ordinary hospitalization only for the most
severe patients and privileges the outpatient or day care
regimen.
The formulation of a specific Diagnostic Therapeutic
Assistance pathway (DTAP) could be a useful tool to de-
fine patients who could actually avoid hospitalization,
without health risks and who would benefit in terms of
psycho-physical wellbeing.
The DTAPs constitute set of services provided in order
to address the patient’s needs from the time of diagnosis
to recovery; they are aimed at managing a specific
pathology in a specific group of patients within a
well-defined local context [21]. The paths are identified
in a multidisciplinary manner to include all the activities
carried out by the different professionals involved to
manage the pathology in question. Depending on the ill-
ness for which the DTAP is implemented, activities may
be planned within a single hospital organizational struc-
ture, or a much wider range of services may be involved,
different in terms of reference discipline and the setting
where they are supplied [22].
A review of literature published in June 2009 [23]
shows that DTAPs may represent an effective mechan-
ism to promote adherence to treatment guidelines and
protocols as they reduce the variability of clinical
practice. The study also found that, for predictable care
pathways, DTAPs can be effective in promoting
proactive disease management and ensuring that
patients receive timely intervention and clinical evalua-
tions. Furthermore, the use of these pathways leads to
greater agreement among clinicians on treatment op-
tions and provides valuable support for decision-making.
The present work therefore aims at drawing up a spe-
cific DTAP for children affected by JIA with the aim of
transferring patients with well defined clinical conditions
from management with regular hospitalization to day or
outpatient regimes. Moreover, we also wanted to assess
whether this pathway is sustainable for a substantial
proportion of patients.
The DTAP is outlined based on the clinical data of
patients admitted to the Intermediate Pediatric Care Unit,
Fondazione IRCCS Ca′ Granda, Ospedale Maggiore
Policlinico of Milan.
Methods
The analysis is based on data from a monocentric study
regarding admissions for JIA in the 2014–2016
three-year period at the Intermediate Pediatric Care Unit,
Fondazione IRCCS Ca′ Granda, Ospedale Maggiore Poli-
clinico of Milan.
The study examined all admissions in the period from
1 January 2014 to 31 December 2016 where the cause of
hospitalization was closely linked to JIA. A total of 223
files were assessed, 89 in 2014, 66 in 2015, and 68 in
2016, respectively. At the end the final population was
made up by 127 patients, given the presence of numer-
ous multiple admissions during the period considered.
Although the study is centered on a pediatric setting,
adults of up to 23 years were also included since patients
continued to be monitored also after the age of 16.
The relevant information was extracted from the
printed medical records and collected in a Microsoft™
Excel database.
Socio-demographic variables (name, surname, noso-
graphic code, date of birth, sex and municipality of resi-
dence), clinical variables of interest (diagnosis in letter of
discharge, associated diseases, general conditions), pres-
ence of indicative clinical signs of systemic compromise
(fever upon admission) were all included in the database.
Data regarding the access modalities to the ward
(planned or urgent hospitalization, transfers from other
wards), variables concerning hospitalization (date of ad-
mission and discharge, reason for admission, diagnostic
investigations, specialist and physiotherapy visits), the
possible execution of surgery in the operating room in
sedation (arthrocentesis intervention) and intravenous
therapy have been recorded too.
Starting from the data collected during the first year of
the study, a DTAP was set up to treat and follow chil-
dren shifting from the regimen, provided by a regular
hospitalization, to a day service model of care Fig. 1.
In particular, the Complex Outpatient Macroactivity
with High Resource Integration (MAC) was identified
as an organizational model set up by the Lombardy
Region dealing with the management of all the
activities that, although having to be carried out in a
hospital context, can be performed in a complex out-
patient procedure.
Elaboration and evaluation of the data lead to select
the following DATP inclusion criteria: active arthritis,
good general clinical conditions, no fever, no symptoms
or signs of systemic involvement, no need of intravenous
therapy or sedation. Consequently, this pathway can’t
apply to patients with systemic JIA.
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The only exception involved admissions due to the
administration of biological therapy. It was assessed that
these could be included in the DATP, as the intravenous
therapy carried out on these occasions was planned and
not linked to the present state of the disease. Further-
more, exclusively in this case, a day service model has
been considerate adequate for children with systemic
JIA, as these admissions didn’t concern a state of onset
or flare of the pathology.
The DTAP was then applied to all the patients’
admissions examined in order to assess what effects its
implementation could have in the clinical reality
investigated.
Statistical analysis
To visualize associations among variables multiple
correspondence analysis has been used [24]. This tech-
nique represents categorical variables into a space with
Fig. 1 DTAP flowchart
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dimensions ordered by the proportion of the total
variability that they explain. The distance between points
in this space is a measure of the dissimilarity between
the corresponding categories. If the original variables are
strongly correlated, the first two axes explain a great
proportion of the overall variability, so that the relation-
ships among categories are well represented in that
plane. DTAP was added as a supplementary variable to
the space determined by the other variables.
The association between inclusion in the pathway and
other variables was investigated by Firth logistic
regression models [25]. Firth’s approach was adopted to
obtain finite odds ratios estimates also in the case of
quasi-complete separation. From the regression models
95% confidence intervals and p-values were also ob-
tained. The analyses were performed with R [26] version
3.4.2 and its add-on packages ca, FactoMineR and logistf.
Results
Demographic features of the 127 patients are summa-
rized in Table 1: 80% of young patients are female, with
a median age of 9 years; 87% of children are resident in
Lombardy region. Applying DTAP criteria, in the three
years period 32% of patients could have avoided
hospitalization completely, and another 23% would have
been hospitalized fewer times.
Inclusion in the DTAP is positively associated with
residence outside Lombardy (OR = 4.12, 95% CI = 1.74–
10.7), x-rays (OR = 2.04, 95% CI = 1.19–3.56) and ortho-
pedic examination (OR = 2.78, 95% CI = 1.29–6.26).
Inclusion in the DTAP was negatively associated with
urgent admission (OR = 0.20, 95% CI = 0.06–0.66),
electrocardiogram (OR = 0.39, 95% CI = 0.21–0.71) and
anesthesiology examination (OR = 0.04, 95% CI = 0.02–
0.09). Furthermore, DTAP is associated with the cause
of the hospitalization, with the odds of inclusion in the
DTAP being smaller for arthrocentesis (OR = 0.07, 95%
CI = 0.01–0.22) and greater for biologic therapy 61.4
(95% CI = 8.03–7894) with respect to flare Table 2.
In the multiple correspondence analysis, the first two
axes explain 75.6% of the total variability, so that
relationships among categories are well represented in
this plane. The plot shows positive association among
the following categories: inclusion in the DTAP, ortho-
pedic examinations, residence outside the region and
hospitalization due to either flare, re-evaluation, associ-
ated conditions or biological therapy. On the contrary,
exclusion from the DTAP is associated to anesthesiology
examination, sedation, arthrocentesis and intravenous
therapy and arthrocentesis-related admissions Fig. 2.
Furthermore, the data concerning the activities carried
out by the Intermediate Pediatric Care Unit for patients
with JIA highlight how the number of admissions has
been reduced from 2014 to 2016. On the contrary, out-
patients’ activities like MAC have been constantly rising
during the observed years Table 3.
Discussion
Starting from the data collected during the first year of
the study, a DTAP was set up to identify patients who
could be treated in regimen alternative to regular
hospitalization. It was therefore a real-time process,
enabling the establishment of a pathway suitable for the
setting of application. In this way, we could evaluate and
modify the hypothesized variables a priori to better
reflect the clinical reality.
The analysis of the 223 cases of admissions of young
JIA patients figured out a picture of the typology of
patients attending the department and the services per-
formed during hospitalization. Regarding the epidemi-
ology of JIA, the data are in line with literature reports:
females are more affected than males, there are children
of all ages, the most represented form is oligoarticular
arthritis, followed by polyarticular and systemic arthritis.
Data examination relative to patient residency showed
that 52% of patients reside in the Milan metropolitan
area, which would make the transition to outpatient
treatment not only feasible but also beneficial, especially
in terms of quality of life, for a sizeable majority of
users.
Out of all the patients considered, as many as 55%
could be impacted by the DTAP. This group would have
completely avoided admissions or reduced their number
over the three-year period.
The characteristics of the subjects and the services
performed during hospitalization were examined and
compared between the group of patients who could be
included in the DTAP and those who would have
confirmed the regular hospitalization pathway. Several
variables were found to be associated with the inclusion
Table 1 Characteristics of the patients
Variable





Milan metropolitan area 66 (52)
Rest of Lombardy 44 (35)
Other regions 17 (13)
Patients whose admissions are eligible for DTAP, n (%)
No admission 57 (45)
Some admissions 29 (23)
All admissions 41 (32)
DTAP diagnostic therapeutic assistance pathway, IQR interquartile range
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Table 2 Results of univariable Firth’s logistic regression: inclusion in the DTAP versus patients and hospitalization characteristics
Variable All (n = 223) Non DTAP (n = 131) DTAP (n = 92) OR (95% CI) P
Condition on admission, n (%)
Not good 40 (18) 40 (31) 0 (0)
Good 183 (82) 91 (69) 92 (100)
Fever on admission, n (%)
No 207 (88) 115 (88) 92 (100)
Yes 16 (7) 16 (12) 0 (0)
Sedation, n (%)
No 133 (60) 41 (31) 92 (100)
Yes 90 (40) 90 (69) 0 (0)
Age, years, median (IQR) 10 (6–14) 10 (5–14) 10 (6–13) 1.01 (0.96–1.06) 0.70
Gender, n (%) 0.10
Male 54 (24) 37 (28) 17 (18) reference
Female 169 (76) 94 (72) 75 (82) 1.71 (0.91–3.32)
Residence, n (%) 0.001
Lombardy 198 (89) 124 (95) 74 (80) reference
Other regions 25 (11) 7 (5) 18 (20) 4.12 (1.74–10.7)
Discharge JIA diagnosis, n (%) 0.12*
Oligoarticular 84 (38) 47 (37) 37 (41) reference
Polyarticular 76 (35) 43 (34) 33 (36) 0.98 (0.52–1.82) 0.94
Systemic 33 (15) 26 (20) 7 (8) 0.36 (0.14–0.86) 0.02
Enthesitis-related 9 (4) 5 (4) 4 (4) 1.04 (0.26–3.91) 0.96
Monoarticular 9 (4) 3 (2) 6 (7) 2.35 (0.62–10.4) 0.21
Psoriatic 8 (4) 4 (3) 4 (4) 1.27 (0.31–5.22) 0.74
Unknown 4 3 1
Urgent admission, n (%) 0.008
No 201 (90) 112 (85) 89 (97) reference
Yes 22 (10) 19 (15) 3 (3) 0.20 (0.06–0.66)
Transfer from other hospital, n (%) 0.34
No 218 (98) 127 (97) 91 (99) reference
Yes 5 (2) 4 (3) 1 (1) 0.35 (0.04–3.06)
First hospitalization, n (%) 0.37
No 196 (88) 113 (86) 83 (90) reference
Yes 27 (12) 18 (14) 9 (10) 0.68 (0.29–1.58)
Length of stay, days, median (IQR) 6 (3–8) 6 (3–9) 6 (3–7) 0.95 (0.89–1.01) 0.11
Cause of hospitalization, n (%) < 0.0001*
Flare 79 (35) 44 (34) 35 (38) reference
Arthrocentesis 47 (21) 45 (34) 2 (2) 0.07 (0.01–0.22) < 0.0001
Investigations for suspected JIA 45 (20) 28 (21) 17 (18) 0.77 (0.36–1.61) 0.49
Clinical and therapeutic re-evaluation 16 (7) 6 (5) 10 (11) 2.02 (0.70–6.22) 0.19
Associated conditions 10 (4) 6 (5) 4 (4) 0.87 (0.22–3.09) 0.83
Biologic therapy 24 (11) 0 (0) 24 (26) 61.4 (8.03–7894) < 0.0001
Arthrocentesis and biological therapy 2 (1) 2 (2) 0 (0) 0.25 (0.00–3.21) 0.32
Electrocardiogram, n (%) 0.002
No 58 (26) 24 (18) 34 (37) reference
Yes 164 (74) 106 (82) 58 (63) 0.39 (0.21–0.71)
Unknown 1 1 0
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Table 2 Results of univariable Firth’s logistic regression: inclusion in the DTAP versus patients and hospitalization characteristics
(Continued)
Variable All (n = 223) Non DTAP (n = 131) DTAP (n = 92) OR (95% CI) P
Ultrasound, n (%) 0.08
No 65 (29) 44 (34) 21 (23) reference
Yes 158 (71) 87 (66) 71 (77) 1.69 (0.93–3.13)
X-rays, n (%) 0.01
No 98 (44) 67 (51) 31 (34) reference
Yes 125 (56) 64 (49) 61 (66) 2.04 (1.19–3.56)
Nuclear magnetic resonance, n (%) 0.66
No 191 (86) 111 (85) 80 (87) reference
Yes 32 (14) 20 (15) 12 (13) 0.84 (0.39–1.79)
Computed tomography, n (%) 0.69
No 219 (98) 129 (98) 90 (98) reference
Yes 4 (2) 2 (2) 2 (2) 1.43 (0.22–9.42)
Positron emission tomography, n (%) 0.20
No 220 (99) 128 (98) 92 (100) reference
Yes 3 (1) 3 (2) 0 (0) 0.20 (0.00–2.08)
Eye examination, n (%) 0.09
No 100 (45) 65 (50) 35 (38) reference
Yes 123 (55) 66 (50) 57 (62) 1.60 (0.93–2.75)
Cardiac examination, n (%) 0.19
No 101 (45) 64 (49) 37 (40) reference
Yes 121 (55) 66 (51) 55 (60) 1.44 (0.84–2.47)
Unknown 1 1 0
Anesthesiology examination, n (%) < 0.0001
No 127 (57) 42 (32) 85 (92) reference
Yes 96 (43) 89 (68) 7 (8) 0.04 (0.02–0.09)
Orthognatodontic examination, n (%) 0.08
No 182 (82) 112 (85) 70 (76) reference
Yes 41 (18) 19 (15) 22 (24) 1.84 (0.94–3.65)
Orthopedic examination, n (%) 0.009
No 193 (87) 120 (92) 73 (79) reference
Yes 30 (13) 11 (8) 19 (21) 2.78 (1.29–6.26)
Dermatological examination, n (%) 0.70
No 209 (94) 122 (93) 87 (95) reference
Yes 14 (6) 9 (7) 5 (5) 0.81 (0.26–2.34)
Otorhinolaryngology examination, n (%) 0.76
No 221 (99) 130 (99) 91 (99) reference
Yes 2 (1) 1 (1) 1 (1) 1.43 (0.11–17.8)
Physical therapy, n (%) 0.96
No 70 (31) 41 (31) 29 (32) reference
Yes 153 (69) 90 (69) 63 (68) 0.99 (0.56–1.76)
Arthrocentesis, n (%) < 0.0001
No 114 (51) 43 (33) 71 (77) reference
Yes 109 (49) 88 (67) 21 (23) 0.15 (0.08–0.27)
Cavazzana et al. Italian Journal of Pediatrics          (2018) 44:139 Page 6 of 9
or exclusion from the pathway. For example, residency
outside the Lombardy region provide four times more
odds of being included in the pathway; this could be
explained by the fact that most of these patients are hos-
pitalized for a clinical re-evaluation or for non-urgent
reasons. Probably, also the limited availability of
supportive accommodation outside the hospital had a
role. On the other hand, urgent admissions, as were
classified all the cases coming from the emergency
room, entail a close correlation with exclusion from the
DTAP as they require more direct assistance than the
outpatient pathway. These hospitalizations, indeed, were
mostly related to more severe cases of JIA at its onset or
relapse and to acute infectious disease in patients with
JIA. Furthermore, as to the causes of hospitalization, it
can be observed that the programmed administration of
biological therapy, compared with the reference category
of the flare, is positively correlated with the DTAP, as
this type of service is well suited to fit the characteristics
of the MAC. Arthrocentesis indeed is negatively corre-
lated, since in most cases it is carried out under sedation
and therefore requires hospitalization. The type of JIA,
instead, doesn’t seem to affect the inclusion or exclusion
from the DTPA. In the two major represented type of
JIA, oligoarticular and polyarticular, the percentage of
admissions included and excluded from the DTAP is
similar to the one relative to all the admissions. Regard-
ing the hospitalizations of patients with systemic JIA,
the majority result excluded from the DTAP (according
to DTAP criteria); the remaining cases were related to
the administration of biologic therapy, as it is the only
case in which a day service it’s been considered proper
for these patients.
The MAC graph concerning the first two axes are
clearly representative of the structure of association
between the variables with 75.6% of total variability.
The results are consistent with the criteria for exclu-
sion from the DTAP, since sedation, arthrocentesis,
Table 2 Results of univariable Firth’s logistic regression: inclusion in the DTAP versus patients and hospitalization characteristics
(Continued)
Variable All (n = 223) Non DTAP (n = 131) DTAP (n = 92) OR (95% CI) P
Intravenous therapy, n (%) < 0.0001
No 104 (47) 24 (18) 80 (87) reference
Yes 119 (53) 107 (82) 12 (13) 0.04 (0.02–0.07)
DTAP diagnostic therapeutic assistance pathway, JIA juvenile idiopathic arthritis, IQR interquartile range, OR odds ratio, CI confidence interval
*Global likelihood ratio test p-value
Fig. 2 First two dimensions plane from the multiple corresponding analysis. Categorical variables: anesthesiology examination (anesthesiology),
arthrocentesis, cardiac examination (cardiac), cause of hospitalization (cause), length of stay, electrocardiogram (ECG), eye examination (eye),
fever on admission (fever), first hospitalization (first), good condition on admission (good condition), intravenous therapy (IV), nuclear magnetic
resonance (NMR), orthognatodontic examination (OG), orthopedic examination (orthopedic), residence outside Lombardy region (distant), physical
therapy (PT), sedation, ultrasound (US), urgent admission (urgent), X-rays. Eligibility to the diagnostic therapeutic care pathway (DTAP) is passively
projected to the plane as a supplementary variable. The percentage of total variability explained by each axis is reported. Other abbreviations:
JIA = juvenile idiopathic arthritis; N = no; Y = yes
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anesthesia evaluation and intravenous therapy are
inter-related each other and with non-inclusion in the
DTAP.
While not yet officially approved by our institutional
board, the way the planned DTAP for JIA patients has
been developed (as result of collaboration between
preventive medicine and pediatricians) may well repre-
sent a pathway to better addressing hospitalization, with
powerful savings in health economics. As part of a trend
promoted by national health policies and by the creation
of the MAC by the Lombardy Region, the number of
MAC-type services increased in the year following the
start of the study, while the normal admissions for the
management of patients with the appropriate character-
istics dropped from 89 in 2014 to 66 in 2015, and 68 in
2016.
Moreover, while there is no evidence of return admis-
sions, continuity of care seems to be ensured as a result
of the provision of assistance through MAC, confirming
the feasibility of introducing alternative solutions to
hospitalization in controlled settings, and, accordingly, a
measurable advantage for the quality of life of young
people with JIA can be realistically predicted.
Conclusions
The use of DTAP to manage JIA patients raises the
possibility of treating the young chronic patient without
hospitalization, or reducing it to the necessary. This can
yield significant benefits, not only from the point of view
of resource optimization, but especially towards the
patients’ quality of life.
The application of the DTAP following its official
approval represents a priority for the continuous
improvement of the clinical practice and quality of life
of patients and their families, and can be considered an
objective to be pursued in a perspective of pediatric
appropriateness.
In the near future, also the evaluation of the customer
satisfaction of parents and children who benefit from
outpatient management of the disease will be
mandatory, to have a full view of the change of interven-
tion policy.
Abbreviations
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